ASP Isotopes Inc. (ASPI)

ASP Isotopes is moving from facility construction toward early commercialization across helium, stable isotopes, radiopharmacy and nuclear fuels. Recent updates include stable liquid-helium production, a proposed South African HALEU joint venture, and a company target of more than $300 million in EBITDA by 2031.